Tuesday, August 08, 2017 1:59:57 AM
If you think back on the timeline of this whole mess. Warner Chilcott was bought by Actavis. Then after that, Actavis and Allergan merged. How many selling drugs were they owners of? How many drug candidates in their combined pipepine? Do you really think that the people at Actavis and then Allergan know about Vitaros until you said it right - Richard Pascoe came knocking?
I doubt they knew about DDAIP either but does it matter? Do they not have enough drugs in their pipeline to not need DDAIP?
The tax write-off scenario? Well I guess I can entertain a scenario like that. But it doesn't have to be only Allergan. It can be any company willing to pay an amount for Apricus for tax benefits and a royalty on Vitaros.
For Apricus shareholders - Yes, they need a sale of the company. But what is $5 now? .50 cents pre reverse split. What's $10 now? $1 pre reverse split. We were here when Apricus' share price was $5. Which would be $50 now. No real value for whoever held on to their shares from our days.
So to answer your question. Yes, I think Allergan thought what do we have to lose? It was a win / win for both companies. They are not obligated to opt-in. Apricus paid Allergan whatever Warner Chilcott paid Apricus for the same rights - Apricus is doing the heavy lifting ( with the money of their shareholders ). And now if approved - Allergan can reap the rewards of a drug they never did any work on. If commercialized they get 20% royalties on a drug they probably didn't even know they had at a certain point.
By the way, and I'm only bringing this up as people here continue to focus on the positives and not on the possible negatives.
Are people aware that Majorelle is suing Apricus and Ferring?
You think that Apricus won't dilute shareholders again if they have to pay Majorelle off? You have to remember that Majorelle was the partner that paid Apricus the most money for Vitaros rights. They paid off the whole FINESCO deal in France which Bassam Damaj got us in.
And yes, the more shares outstanding - the lower the possible sell price of the company per share.
Recent SEEL News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2024 12:53:01 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/25/2024 10:09:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2024 08:05:35 PM
- Biotech Soars On Material Transfer Agreement • AllPennyStocks.com • 09/24/2024 07:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 01:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/26/2024 04:15:16 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/20/2024 08:01:49 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/16/2024 08:02:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/09/2024 08:02:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:06:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/26/2024 08:01:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 08:05:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 01:15:52 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/14/2024 08:06:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:05:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:01:36 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/20/2024 08:16:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 01:00:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 03:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 12:00:41 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/06/2024 10:32:04 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM